Enrollment now complete for Phase 2 PROSEEK study of vodobatinib
Enrollment is now complete for a Phase 2 trial that’s assessing the safety and efficacy of oral vodobatinib (K0706), an experimental Abl inhibitor, in people with early Parkinson’s disease across 84 clinical sites in the U.S., Europe, and India. The placebo-controlled trial (NCT03655236), dubbed PROSEEK and sponsored by Sun…